Non-meningeal, non-pulmonary cryptococcosis with limited posterior uveitis in a kidney organ transplant recipient with antibody-mediated rejection: a case report

Table 2 Treatment recommendations for CNS or disseminated disease or severe pulmonary disease in transplant recipients^a

	IDSA, 2010	AST IDCOP, 2019	Our case
Induction therapy	L-AmB (3–4 mg/kg/d) or ABLC (5 mg/kg/d) plus 5-FC (100 mg/kg/d), 2 weeks	L-AmB (3–4 mg/kg/d)^b or ABLC (5 mg/kg/d) plus 5-FC (100 mg/kg/d), minimum of 2 weeks	L-AmB 4 mg/kg/d, 3 wks
Alternatives for induction therapy	L-AmB (6 mg/kg/d) or ABLC (5 mg/kg/d) or AmBd (0.7 mg/kg per day), 4–6 weeks	L-AmB (3–4 mg/kg/d) or ABLC (5 mg/kg/d), minimum of 4–6 weeks	L-AmB 4 mg/kg/d, 3 wks
Consolidation therapy	Fluconazole 400–800 mg/d, 8 weeks	Fluconazole 400–800 mg/d, 8 weeks	Fluconazole 200 mg/d, about 6 months
Maintenance therapy	Fluconazole 200–400 mg/d, 6–12 months	Fluconazole 200–400 mg/d, minimum of 6–12 months	Fluconazole 200 mg/d, about 6 months

ABLC, amphotericin B lipid complex; L-AmB, Liposomal amphotericin B; AmBd, amphotericin B deoxycholate; 5-FC, 5-fluorocytosine
^a Dosages of medicine mentioned above are in the absence of renal insufficiency. All require dose adjustment for renal insufficiency
^b Lipid formulation of amphotericin B plus 5-flucytosine is preferred as induction therapy

ISSN: 1471-2415